Consumer comments open for CAR-T cell therapy funding for myeloma in Australia What is CAR-T cell therapy? CAR-T stands for ‘Chimeric Antigen Receptor T Cell’ and is a type of treatment known as an im...
Apr 2021 30
Every week, 38 Australians are diagnosed with myeloma, an incurable blood cancer that develops in the bone marrow. Despite this, many people have never heard of myeloma until they, or a loved one, are...
Dec 2020 27
Myeloma Australia welcomes today’s announcement by the Federal Government that the medicine Darzalex® (also known as daratumumab) will be available on the Pharmaceutical Benefits Scheme (PBS) for Aust...
May 2020 23
At the upcoming Pharmaceutical Benefits Advisory Committee (PBAC) meeting in July, there will be two submissions made relating to drugs that are used to treat myeloma, namely daratumumab and carfilzom...
Apr 2020 02
Lenalidomide (Revlimid®) maintenance post autologous stem cell transplant We are delighted to announce that as of 1 April 2020 the pharmaceutical benefits scheme (PBS) have listed lenalidomide (Revlim...
Mar 2020 13
Our Information and Support Groups are informal gatherings for people living with myeloma, their family and friends. These meetings provide a safe space to meet other members of the myeloma community ...
Dec 2019 20
Earlier this month, a team from Myeloma Australia visited Orlando, Florida in the USA for the annual American Society of Hematology (ASH) conference as invited guests of the International Myeloma Foun...
Sep 2019 19
A couple of weeks ago we sent out a special advocacy edition of the Muster to inform you of the latest submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for the upcoming November PB...
Sep 2019 13
Cytogenetics is the study of chromosomes within a cell. Most commonly done at diagnosis, cytogenetic testing identifies the genetic mutations which characterise a person’s myeloma. This information he...